Annual report pursuant to Section 13 and 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Total net revenues $ 2,532,499 $ 4,803
Total operating loss (7,973,228) (4,011,058)
Non-operating income (expense), net 57,210 (4,140,596)
Net loss before income taxes (7,916,018) (8,151,654)
Income tax expense (20,993) (2,459)
Net Loss (7,937,011) (8,154,113)
Diagnostic R&D [Member]    
Product Information [Line Items]    
Total net revenues 19,442
Total operating loss (1,724,597) (1,524,170)
Laboratory Services [Member]    
Product Information [Line Items]    
Total net revenues 2,513,057 4,803
Total operating loss (3,769,783) (95,041)
General Corporate Activities [Member]    
Product Information [Line Items]    
Total operating loss $ (5,011,347) $ (2,396,650)